This was accomplished by quantifying the proportion of CD103+CD8+ T cells and assessing the expression levels of PD-1 and TIGIT in the peripheral blood of AML and B-ALL patients with diverse outcomes, utilizing multi-color flow cytometry. The gene discussed is CD8A; the disease is acute lymphoblastic leukemia.